MGC Pharma has provided an update on its activities, stating it has made strong progress across its clinical pipelines.
MGC Pharmaceuticals has stated that it now has multiple completed trial results indicating efficacy across its product range. This includes important trial results for its products CogniCann and CimetrA.
Preclinical in vitro study results announced in June indicate that CimetrA™, MGC Pharma’s proprietary Investigation Medicinal Product (IMP), has a wide-ranging application as an anti-inflammatory treatment through the modulation of the production of pro-inflammatory cytokines.
Read more: Phytocannabinoid company MGC Pharma initiates study for long-COVID
It has also completed a Phase II Clinical Trial for its proprietary dementia treatment, CogniCann, which has demonstrated its full safety and preliminary efficacy profile. The trial, which was undertaken by the University of Notre Dame in Western Australia, demonstrated that the THC and CBD-based product can inhibit the deterioration in the behaviour of patients with dementia.
Co-founder and managing director of MGC Pharmaceuticals, Roby Zomer, commented: “MGC Pharma remains resolutely focused on advancing its innovative products through the clinical pipeline of product development and continues to progress a number of products towards regulatory approval.
“This has been supported by strong clinical trial results and partnerships with companies such as Sciensus Rare and AMC Holdings that will help us achieve our goals.
“Getting pharmaceutical products through the regulatory approval process takes time, particularly when the products are phytocannabinoids.
“I am, however, confident in the team and the strategy that has been developed to help ensure this process and that MGC Pharma’s products will be able to make a difference to patients suffering with debilitating conditions.”
The company has also been collaborating with the National Institute of Biology in Slovenia, MGC announcing the completion of a successful in vitro preclinical research study into the use of cannabinoids to treat Glioblastoma multiforme cells, a fast-growing and aggressive form of brain cancer.
The findings will be the subject of further research studies to determine the efficacy of MGC Pharma’s Glioblastoma treatment formulation in a clinical trial setting.
The Slovenian Intellectual Property Office (SIPO) granted MGC Pharma a patent which provides the company commercial protection over the intellectual property associated with CimetrA™, its unique formation and manufacturing process for a period of 20 years.
MGC Pharma also announced the grant of a second patent by SIPO, for its IMP CannEpil – its proprietary treatment for Refractory Epilepsy. The grant of the CannEpil patent provides MGC Pharma commercial protection over the intellectual property associated with CannEpil-IL, its formulation and manufacturing process for 20 years.
[activecampaign form=31]
